Conflict of interest: A.T. has received a research grant from AstraZeneca R&D. K.M.H. is employed at the AstraZeneca R&D. M.E. and S.Å. have no conflict of interest in relation to this study.
Reduced risk of death with warfarin – results of an observational nationwide study of 20 442 patients with atrial fibrillation and ischaemic stroke
Article first published online: 29 AUG 2012
© 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization
International Journal of Stroke
Volume 8, Issue 8, pages 689–695, December 2013
How to Cite
Åsberg, S., Eriksson, M., Henriksson, K. M. and Terént, A. (2013), Reduced risk of death with warfarin – results of an observational nationwide study of 20 442 patients with atrial fibrillation and ischaemic stroke. International Journal of Stroke, 8: 689–695. doi: 10.1111/j.1747-4949.2012.00855.x
Funding: Riks-Stroke is funded by the National Board of Health and Welfare, and the Swedish Association of Local Authorities and Regions. S.Å. has received a research scholarship from the National Association for Stroke Patients in Sweden (Stroke-Riks Förbundet).
- Issue published online: 25 NOV 2013
- Article first published online: 29 AUG 2012
- AstraZeneca R&D
- National Board of Health and Welfare
- Swedish Association of Local Authorities and Regions
|ijs855-sup-0001-si.pdf||62K||Table S1. Basic characteristics of 15 803 patients discharged alive with atrial fibrillation and ischemic stroke by antithrombotic therapy and subclassification on the propensity score for warfarin.|
|ijs855-sup-0001-si.pdf||62K||Table S2. Adjusted risk of death in 15 803 patients with atrial fibrillation and ischemic stroke on warfarin versus antiplatelets by subclassification on the propensity score for warfarin.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.